While correlative tissue studies with phospho-AKT measures have shown the more commonly found negative correlation between increased AKT activation and clinical outcome, it is possible that there is a subset of pancreas cancer, similar to studies in non-small cell lung cancer, where phospho-AKT levels as a measure of EGFR-PI3K-AKT signaling have been shown to be associated with improved outcome [54–57]. The gene discussed is EGFR; the disease is pancreatic neoplasm.